Exhibit 99.1 SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 31, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2024. Total revenues in the second quarter of 2024 grew 20 percent year-over-year to $714.9 million, compared to $596.5 million in the second quarter of 2023. Key financial highlights include (dollars in millions, except per share data): United Therapeutics Corporation Reports Second ...

Part I. Financial Information | --- | --- | --- | --- | --- | |-------------------------------------|-------|----------------------------|-----------------------------|----------------------| | Due within one year | $ | Amortized Cost \n 1,632.2 | As of June 30, 2024 \n \n$ | Fair Value \n1,622.1 | | Due in one to three years | | 1,337.2 | | 1,330.4 | | Total | $ | 2,969.4 | $ | 2,952.5 | As of June 30, 2024 and December 31, 2023, we maintained non-controlling equity investments in privately-held companies ...

The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits. Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels. UTHR currently has a forward P/E ratio of ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. It also includes access to the Zacks Style Scores. The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest ...

The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits. UTHR sticks out from CTLT in both our Zacks Rank and Style Scores models, so value investors will likely feel that UTHR is the better option right now. United Therapeutics and Catalent ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all. However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cuttingedge growth stocks. Studies have shown that stocks with the best gro ...

Given these factors, it shouldn't be surprising that UTHR is a #2 (Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep United Therapeutics on your short list. Earnings Outlook The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have re ...

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. Currently, United Therapeutics has a Zacks Rank of #2 (Buy), while Catalent has a Zacks Rank of #5 (Strong Sell). This means that UTHR's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analys ...

Have you been paying attention to shares of United Therapeutics (UTHR) ? Shares have been on the move with the stock up 11.6% over the past month. The stock hit a new 52-week high of $330 in the previous session. United Therapeutics has gained 46.2% since the start of the year compared to the 7.5% move for the Zacks Medical sector and the -3.5% return for the Zacks Medical - Drugs industry. For the current fiscal year, United Therapeutics is expected to post earnings of $24.85 per share on $2.71 billion in ...

United Therapeutics (UTHR) announced full enrolment in the phase III TETON 2 study evaluating a nebulized version of Tyvaso (treprostinil) in patients with idiopathic pulmonary fibrosis (IPF), a scarring disease of the lungs. The TETON 2 study is now enrolled with a total of 597 patients. Top-line data from this study is expected in second-half 2025. The FDA has already approved Tyvaso as an inhalation solution (nebulized) and dry powder inhaler (DPI) for treating pulmonary arterial hypertension (PAH) and p ...